Search
Search Results
##search.searchResults.foundPlural##
-
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1289HTML: 363PDF: 789 -
THE CHALLENGE OF AML IN OLDER PATIENTS
2122PDF: 915HTML: 2144 -
miR-155-5p PROMOTES CD34+ APOPTOSIS AND INHIBITS BONE MARROW HEMATOPOIESIS IN MYELODYSPLASTIC SYNDROMES BY RAC1/CREB/MIR-15B AXIS
664PDF: 784PDF Supp. Files: 68HTML: 170 -
IMMUNE THROMBOCYTOPENIA ONSET AND RELAPSE DURING THE COVID19 PANDEMIC. A MONOCENTER STUDY. ITP and COVID19 infection and vaccination
1253PDF: 771HTML: 294 -
PRACTICAL RECOMMENDATIONS FOR THE MANAGEMENT OF PATIENTS WITH ITP DURING THE COVID-19 PANDEMIC Recommendation for ITP management during COVID
2296PDF: 884HTML: 482 -
THERAPEUTIC VALUE OF COMBINED THERAPY WITH DEFERASIROX AND SILYMARIN ON IRON OVERLOAD IN CHILDREN WITH BETA THALASSEMIA
2498PDF: 799HTML: 14927Therapeutic Value of Combined Therapy with Deferasirox and Silymarin on Iron Overload in Children with Beta Thalassemia: 273 -
MODERN IMMUNOTHERAPY OF ADULT B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA WITH MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS
2204PDF: 1290HTML: 17056Bassan Fig.1: 133Bassan Fig.2: 129Bassan Fig.4: 126Fig.3: 162 -
MYELODYSPLASTIC SYNDROMES AND IRON CHELATION THERAPY
3303PDF: 1255HTML: 1845Fig.1: 180Fig. 2: 186 -
AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA: NON-RANDOMIZED STUDY WITH A MAXIMUM FOLLOW-UP OF MORE THAN 22 YEARS
1484PDF: 875HTML: 1933Figure: 150Tables: 164ALL revision 1: 174response to reviewer: 159 -
OPTIMIZING TREATMENT, MINIMIZING RISK: THERAPEUTIC DRUG MONITORING IN HEMATOLOGICAL MALIGNANCIES
766PDF: 899Suppl. Files: 112HTML: 62 -
Azacytidine failure revisited: an appraisal based on real life data from the MDS registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS). Azacytidine failure revisited
1051PDF: 815HTML: 219 -
Treating relapsed/refractory acute myeloid leukemia with chidamide, fludarabine, cytarabine and granulocyte-colony stimulating factor with subsequent bridging to myeloablative allogeneic hematopoietic stem cell transplantation Treating relapsed/refractory acute myeloid leukemia with chidamide, fludarabine, cytarabine and G-CSF
1675PDF: 544HTML: 258 -
TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA
3226PDF: 1429HTML: 3974 -
CONCISE REVIEW ON THE FREQUENCY, MAJOR RISK FACTORS AND SURVEILLANCE OF HEPATOCELLULAR CARCINOMA (HCC) IN ?-THALASSEMIAS: PAST, PRESENT AND FUTURE PERSPECTIVES Thalassaemia transfusion dependent, Hepatitis C, hepatocarcinoma.
4127PDF: 1486HTML: 426 -
-
DIAGNOSIS OF MALARIA INFECTION WITH OR WITHOUT DISEASE
3519PDF: 1080HTML: 23314 -
ALLOGENEIC TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA
1312PDF: 731HTML: 930 -
THALIDOMIDE AMELIORATES ERYTHROPOIESIS AND IRON HOMEOSTASIS IN TRANSFUSION-DEPENDENT β-THALASSEMIA Thalidomide ameliorates erythropoiesis and iron homeostasis
1301PDF: 1377PDF: 986HTML: 187 -
HAS HEMATOPOIETIC STEM CELL TRANSPLANTATION A ROLE IN THE TREATMENT OF CHILDREN AND ADOLESCENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA? Acute Promyelocytic Leukemia and Hematopoietic Stem Cell Transplantation
1041PDF: 712HTML: 184 -
IS THERE A ROLE FOR MINIMAL RESIDUAL DISEASE MONITORING IN FOLLICULAR LYMPHOMA IN THE CHEMO-IMMUNOTHERAPY ERA?
3298PDF: 1246HTML: 2190Fi.1 Gritti.Rambaldi: 185 -
SUSTAINED REMISSION IN AN ELDERLY PATIENT WITH ACUTE MYELOID LEUKEMIA FOLLOWING GILTERITINIB TREATMENT AS THIRD-LINE SALVAGE THERAPY Long-lasting disease remission with third line therapy with gilteritinib
898PDF: 485HTML: 171 -
RECENT ADVANCES IN THE 5Q- SYNDROME
2680PDF: 1752HTML: 3631Pellagatti Fig 1: 186Pellagatti Fig. 2: 183 -







